RE: Post #: 75254781
Hi @Timm-Dah,
re your comment: " (Trump v Harris) ...That result can affect FDA decisions, particularly stem-cell ones with Republican parties not tending to like new-found science that has companies "playing God"...":
I like to see threads stay close to their central theme, but political opinions seem to find their way into everything these days. Polarisation is a dangerous fact of life, it seems. Your suggestion about the position of 'Republican parties' is not a view that I share, so I thought I'd add some (potentially) relevant facts to the discussion:
- Donald Trump's tenure as the 45th president of the United States began with his inauguration on January 20, 2017, and ended on January 20, 2021. Ref: https://en.wikipedia.org/wiki/Presidency_of_Donald_Trump
- During the 115th Congress (2017-2019) the USA House of Representatives was majority-controlled by Republicans.
Ref: https://en.wikipedia.org/wiki/Party_divisions_of_United_States_Congresses.
- Scott Gottlieb, MD was appointed by then-President D. Trump as FDA Commissioner in May 2017. Gottlieb's views apparently continued to enjoy President Trump's interest, even after eventually being replaced by the Biden administration, e.g. https://www.statnews.com/2021/09/21/scott-gottlieb-trump-shadow-commissioner/
- The August 28, 2017 speech by Gottlieb linked here focusses on 'stem' cell research & the role of the FDA. I encourage all MSB holders to read the statement in full, especially the comments on Regenerative Medicines Advanced Therapy (RMAT) and cellular therapies:
...and, in particular:
So, IMO this is one of the most definitive & compelling statements of forward planning on the FDA's proper approach to cellular therapies. It was spoken & publicised with the full authority of the Republican-nominee appointment FDA Commissioner, under a Republican Congress, under a Republican President.
One might speculate as to what has caused delays over the years since then, the role of COVID-19 etc.
But, as a present factual matter that I'd suggest is relevant to the future of the FDA's GVHD therapies under a Republican administration, there's this:
...and this in the last 7 days:
https://www.c-span.org/video/?c5085753/house-majority-leader-steve-scalise-update-cancer-treatment
Food for thought, I'd suggest.
Cheers all.
GLTA(LT)H
- Forums
- ASX - By Stock
- MSB
- MESO Nasdaq update
MESO Nasdaq update, page-5745
-
- There are more pages in this discussion • 228 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.46 |
Change
0.010(0.69%) |
Mkt cap ! $1.667B |
Open | High | Low | Value | Volume |
$1.46 | $1.49 | $1.44 | $3.472M | 2.379M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 12398 | $1.46 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.47 | 5440 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 12398 | 1.460 |
2 | 19558 | 1.455 |
5 | 49977 | 1.450 |
5 | 102249 | 1.445 |
2 | 30389 | 1.440 |
Price($) | Vol. | No. |
---|---|---|
1.465 | 5440 | 3 |
1.470 | 22187 | 2 |
1.475 | 84389 | 3 |
1.480 | 118230 | 9 |
1.485 | 96793 | 8 |
Last trade - 16.10pm 21/10/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
LGP
LITTLE GREEN PHARMA LTD
Paul Long, Chief Executive Officer
Paul Long
Chief Executive Officer
SPONSORED BY The Market Online